S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
Log in

NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, Forecast & News

$13.84
+0.23 (+1.69 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$13.29
Now: $13.84
$14.30
50-Day Range
$13.30
MA: $14.74
$17.19
52-Week Range
$6.44
Now: $13.84
$18.67
Volume60,521 shs
Average Volume58,343 shs
Market Capitalization$356.73 million
P/E RatioN/A
Dividend YieldN/A
Beta4.13
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.48 per share

Profitability

Net Income$-20,650,000.00

Miscellaneous

Employees16
Market Cap$356.73 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.


Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.03. View Verrica Pharmaceuticals' Earnings History.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Verrica Pharmaceuticals.

What price target have analysts set for VRCA?

1 brokerages have issued 12-month target prices for Verrica Pharmaceuticals' shares. Their forecasts range from $24.00 to $24.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.

What is the consensus analysts' recommendation for Verrica Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.

Has Verrica Pharmaceuticals been receiving favorable news coverage?

News stories about VRCA stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Verrica Pharmaceuticals.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totalling 682,800 shares, an increase of 18.2% from the October 31st total of 577,700 shares. Based on an average daily trading volume, of 59,900 shares, the short-interest ratio is presently 11.4 days. Currently, 5.6% of the shares of the company are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the folowing people:
  • Mr. Ted White, Pres, CEO & Director (Age 54)
  • Mr. Chris Degnan, Chief Financial Officer (Age 39)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)
  • Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)
  • Christopher G. Hayes, Sec.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Kornitzer Capital Management Inc. KS (1.83%), State Street Corp (0.81%), Rhumbline Advisers (0.07%) and Barclays PLC (0.02%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.

Which major investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS and Barclays PLC. View Insider Buying and Selling for Verrica Pharmaceuticals.

Which major investors are buying Verrica Pharmaceuticals stock?

VRCA stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp and Rhumbline Advisers. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $13.84.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $356.73 million. The company earns $-20,650,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.View Additional Information About Verrica Pharmaceuticals.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is http://www.verrica.com/.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]


MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel